The Next Era of Biosimilars: Rewriting the Playbook | Virtual Event | STAT

Open original

This is a virtual panel discussion about removing barriers to biosimilar access and affordability. Speakers from Teva and a healthcare advisory firm will discuss how policy changes like interchangeability rules and better payer economics can make biosimilars easier for patients to get.

  • Early biosimilar launches faced friction around access, pharmacy policies, and insurance coverage that complicated patient access
  • Policy shifts like interchangeability designations and reformed health-plan economics are key to reducing friction in the biosimilar market
  • Alignment between policy, supply reliability, and payer incentives is necessary to make biosimilars affordable and accessible

STAT is hosting a virtual event on October 19, 2026, called "The Next Era of Biosimilars: Rewriting the Playbook." The 30-minute session focuses on removing barriers that patients face when accessing biosimilar drugs. The core problem they're addressing is real: early biosimilar launches have been messy. Insurance coverage gaps, pharmacy policies, and complex access requirements have kept patients from getting these lower-cost alternatives to expensive biologics. The event will examine how policy changes—specifically interchangeability designations and better insurance plan economics—could actually make biosimilars easier to get and afford. Two speakers bring serious credentials to this conversation. Thomas Rainey runs Teva's U.S. biosimilars division and has spent three decades in pharma, working through sales, marketing, and market access across oncology and immunology. Roxanne Schwans founded OmniHealthRx Advisors and has spent 30+ years working on both sides of the equation—at drug manufacturers, pharmacy benefit managers, and health systems. She has the rare vantage point of understanding how biosimilar competition actually plays out across the entire supply chain. This is a branded event from STAT's content studio, not independent journalism. That matters for context—STAT's editorial team didn't report or produce it, which is standard disclosure for sponsored content. If you work in pharma, payer strategy, or market access, this would give you a direct line to people actually wrestling with biosimilar adoption problems.

Ask about this article